Skip to main content

Volume 12 Supplement 2

Advanced breast cancer therapy


Edited by Jenny Chang

Publication of this supplement has been sponsored by Bristol Myers Squibb Company. Translation services and administrative support was provided to the authors by Thomson Reuters, Healthcare and Science.

  1. Perou's molecular classification defines tumors that neither express hormone receptors nor overexpress HER2 as triple-negative (TN) tumors. These tumors account for approximately 15% of breast cancers. The so-...

    Authors: Reinaldo D Chacón and María V Costanzo
    Citation: Breast Cancer Research 2010 12(Suppl 2):S3

Annual Journal Metrics